Retatrutide

Retatrutide

Research peptide

Triple GLP-1/GIP/glucagon agonist · phase 3 complete · up to 28.3% weight loss at 80 weeks (30.3% at 2 years)

Strong evidence
Phase 3 complete · BLA announced for 2027What this means ›
🇺🇸 United States · Phase 3 complete

Phase 3 trials have read out; the approval application is not yet filed in United States. Eli Lilly's TRIUMPH programme has now read out in full. TRIUMPH-1 (pivotal, 2,339 adults): up to 28.3% body weight, the highest figure recorded for a single obesity medicine. TRIUMPH-4 (with knee osteoarthritis): 28.7% at 68 weeks. On 23 July 2026 the last two reported: TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes) 12.7% to 20.8% at 80 weeks versus 4.0% on placebo, with A1C down up to 1.6 points; and TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease) 21.6% to 22.6% at 80 weeks versus 3.2% on placebo, plus improvements in lipids, blood pressure, hsCRP and waist. Lilly announced it will file for approval in the first quarter of 2027. In June 2026 the TRIUMPH-1 baskets were presented: knee osteoarthritis pain −73.1% (4.3 points; −75.8% in TRIUMPH-4, the dedicated trial) and moderate-to-severe sleep apnea −60.6% (36 fewer events per hour); TRIUMPH-1 was published in NEJM (June 2026, ADA) and on 29 September 2026 TRIUMPH-2 was published in full in The Lancet (EASD 2026). In type 2 diabetes without obesity, TRANSCEND-T2D-1 read out in March 2026 and was published in full in The Lancet in June 2026. The dedicated cardiovascular trial (TRIUMPH-Outcomes) reports around 2028–2029. What the class has shown and is still unmeasured here: heart and kidney (TRIUMPH-Outcomes, primary completion February 2029) and liver inflammation. Next step: filing the approval application.

Completing phase 3 is NOT approval. Retatrutide is not approved by the FDA or any other agency, and will not be until 2027 or 2028 if the filing succeeds. It remains an investigational compound. Lilly, on its own page (September 2026), states that it is not approved by any agency and that it is distributed only inside its trials. What CAN be checked in a vial, by independent analysis (HPLC and mass spectrometry), is its identity, purity and content: that is why every lot of ours carries a verifiable certificate of analysis. What no analysis can give is clinical approval: it remains research-use-only material.

Source: Eli Lilly · TRIUMPH-1 (may 2026; canastas jun 2026; NEJM jun 2026), TRIUMPH-2 y TRIUMPH-3 (23 jul 2026; TRIUMPH-2 en The Lancet 29 sep 2026), TRIUMPH-4 (11 dic 2025), TRANSCEND-T2D-1 (mar y jun 2026, The Lancet) · FAQ de Lilly «What to know about retatrutide» (sep 2026) · TRIUMPH-Outcomes NCT06383390

OverviewProtocolsPreparation and dosingEvidenceSafetyQuestions

Overview

What has it been researched for?

  • Controls appetite and satiety Main focusStrong evidence
  • Lowers body weightStrong evidence
  • Reduces liver fatStrong evidence
  • Improves glucose controlStrong evidence
  • Improves lipids and blood pressureStrong evidence
  • Raises energy expenditureEarly evidence
  • Reduces sleep apneaStrong evidence
  • Less joint painStrong evidence
  • Slower pace of agingEarly evidence

Research protocols

The SBL research protocol and what the literature reports. Not medical advice.

SBL research protocol · no established clinical regimen in people

Dose
1.5 → 3 mg
Frequency
1×/semana
Duration
16 weeks
Route
Subcutaneous
Evidence level
Human study

Tools

Reconstitution calculatorConverts mg to units (U-100), volume and concentration.Open calculator →Preparation (step by step)How to reconstitute, store and handle, with good practice.See the guide →My trackingLog doses, results and notes per goal, in the app.Go to my tracking →

Evidence and studies

See studies →
Strong evidence(7)Moderate evidence(0)Early evidence(2)

Protocols

Research protocols

SBL research protocol · no established clinical regimen in people

Research use, with no established clinical regimen in people.

Dose
1.5 → 3 mg
Frequency
1×/semana
Timing
cualquier hora
Duration
16 weeks
Break
No break
Route
Subcutaneous
Evidence level
Human study

Example dose

05010015
15 u= 1.5 mg

100-unit U-100 insulin syringe · Starting dose of its protocol, with 1 ml of water in the 10 mg vial.

What it pairs with

Preparation and dosing

Quick reference

Vial10 mg
Diluent1 ml
Concentration10 mg/ml
1 unit =0.1 mg

Preparation

Diluent
Bacteriostatic water

Open calculator →See the guide →

Evidence

Each effect with its evidence level and, where available, its source.

Strong evidence(7)Moderate evidence(0)Early evidence(2)
  • Controls appetite and satietyHuman studySee study · 2025
  • Lowers body weightPhase 3See study · 2026
  • Reduces liver fatHuman studySee study · 2024
  • Improves glucose controlPhase 3See study · 2026
  • Improves lipids and blood pressurePhase 3See study · 2026
  • Raises energy expenditurePreclinicalSee study · 2022
  • Reduces sleep apneaPhase 3See study · 2026
  • Less joint painPhase 3See study · 2026
  • Slower pace of agingExtrapolatedSee study · 2026

The science

Mechanisms, studies and references

Triple agonist

Safety

It makes sense if you want

  • Lose weight — most potent
  • Lose weight & curb appetite
  • Longevity & deep anti-aging

It does not make sense if

  • Personal or family history of medullary thyroid cancer or MEN2
  • Active cancer or oncology treatment in the last 5 years
  • Pregnancy or breastfeeding
  • Gastroparesis or slow gastric emptying
  • Active eating disorder

Talk to your doctor first if this applies (17)

  • Oral contraceptive (the pill)
  • Severe heart disease or recent cardiac event
  • Major surgery in the last 3 months
  • Type 1 diabetes
  • Type 2 diabetes / prediabetes
  • Gallbladder disease or gallstones
  • GLP-1 (Ozempic, Wegovy, Mounjaro, Saxenda)
  • Severe liver impairment
  • Severe kidney impairment
  • Insulin
  • Blood pressure meds
  • Thyroid meds
  • History of pancreatitis
  • Planning a pregnancy in the next 3 months
  • Diabetic retinopathy
  • Sulfonylureas / metformin
  • Thyroid disorder

The certificate of analysis (CoA) certifies the identity and purity of the batch. It does not certify safety of use.

Verify your batch →

For research use only (RUO). This consult is educational and does not replace your doctor.

Questions

Frequently asked questions

What is it reconstituted with, and how much?

With bacteriostatic water: 1 ml into the 10 mg vial, giving 10 mg/ml.

What is the starting dose of the research protocol?

1.5 → 3 mg, 1×/semana. This is the SBL research protocol, with no established clinical regimen in people.

How long is the cycle, and how long does a vial last?

16 weeks. At the starting dose, the 10 mg vial lasts ~3 sem.

Which route is used in research?

Subcutaneous.

When does it make no sense?

It makes no sense with: Personal or family history of medullary thyroid cancer or MEN2, Active cancer or oncology treatment in the last 5 years, Pregnancy or breastfeeding, Gastroparesis or slow gastric emptying, Active eating disorder. Details in the Safety tab.

What is it combined with?

It goes well with MOTS-c. The reasons are in the Protocols tab.

How do I check my batch?

With the code on the vial, in the verifier. The CoA certifies the identity and purity of the batch, not safety of use.

Verify your batch →

See kit

For research use only (RUO). This consult is educational and does not replace your doctor.